Sunitinib (Sutent)

DRUG6 trials

Conditions

Blood PressureBreast NeoplasmsEsophageal CancerMetastatic Renal Cell CarcinomaRenal Cell Carcinoma

Phase 1

Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

CompletedNCT00291577

PfizerBreast Neoplasms

Start: 2006-07-31End: 2009-02-28Updated: 2009-12-23

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

CompletedNCT00788060

Daniel George, MDRenal Cell Carcinoma

Start: 2008-10-31End: 2012-12-31Updated: 2015-02-16

An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers

CompletedNCT00904657

University of CologneBlood Pressure

Start: 2008-10-31End: 2009-04-30Updated: 2009-12-04

Phase 2

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

CompletedNCT00400114

University Health Network, TorontoEsophageal Cancer

Start: 2006-09-25End: 2016-09-19Updated: 2017-05-08

Phase 3

Sequential Study to Treat Renal Cell Carcinoma

CompletedNCT00732914

Sponsor GmbHRenal Cell Carcinoma

Start: 2009-01-31End: 2013-12-31Updated: 2014-04-23

Phase 4

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

TerminatedNCT00930345

Assistance Publique - Hôpitaux de ParisMetastatic Renal Cell Carcinoma

Start: 2008-12-31End: 2013-10-31Updated: 2015-04-01

Related Papers

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial

Clinical Cancer Research2018-07-3016 citations

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

European Urology2015-05-04142 citations

Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Journal of Clinical Oncology2014-05-2012 citations

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Journal of Clinical Oncology2014-02-0144 citations

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

2011-07-0722 citations